These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10990150)

  • 1. Does desensitization to hexarelin occur?
    Rahim A; Shalet SM
    Growth Horm IGF Res; 1998 Apr; 8 Suppl B():141-3. PubMed ID: 10990150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone status during long-term hexarelin therapy.
    Rahim A; O'Neill PA; Shalet SM
    J Clin Endocrinol Metab; 1998 May; 83(5):1644-9. PubMed ID: 9589671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin.
    Rahim A; O'Neill PA; Shalet SM
    Clin Endocrinol (Oxf); 1999 Jan; 50(1):77-84. PubMed ID: 10341859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging.
    Ghigo E; Arvat E; Gianotti L; Grottoli S; Rizzi G; Ceda GP; Boghen MF; Deghenghi R; Camanni F
    Eur J Endocrinol; 1996 Oct; 135(4):407-12. PubMed ID: 8921821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-week treatment with hexarelin in young dogs: evaluation of the GH responsiveness to acute hexarelin or GHRH administration, and of the orexigenic effect of hexarelin.
    Rigamonti AE; Cella SG; Marazzi N; Müller EE
    Eur J Endocrinol; 1999 Sep; 141(3):313-20. PubMed ID: 10474131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.
    Ghigo E; Arvat E; Gianotti L; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F
    J Clin Endocrinol Metab; 1994 Mar; 78(3):693-8. PubMed ID: 8126144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity.
    Massoud AF; Hindmarsh PC; Matthews DR; Brook CG
    Clin Endocrinol (Oxf); 1996 May; 44(5):555-62. PubMed ID: 8762732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The GH-releasing effect of Hexarelin, a synthetic hexapeptide, in newborns is lower than in young adults.
    Bartolotta E; Bellone J; Aimaretti G; Arvat E; Benso L; Deghenghi R; Camanni F; Ghigo E
    J Pediatr Endocrinol Metab; 1997; 10(5):491-7. PubMed ID: 9401905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans.
    Arvat E; Maccagno B; Ramunni J; Giordano R; Broglio F; Gianotti L; Maccario M; Camanni F; Ghigo E
    Eur J Endocrinol; 2000 Nov; 143(5):601-6. PubMed ID: 11078983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
    Massoud AF; Hindmarsh PC; Brook CG
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypothalamic control of growth hormone (GH) secretion in type I diabetic men: effect of the combined administration of GH-releasing hormone and hexarelin, a novel GHRP-6 analog.
    Giustina A; Desenzani P; Perini P; Deghenghi R; Bugari G; Wehrenberg WB; Giustina G
    Endocr Res; 1996 May; 22(2):159-74. PubMed ID: 8799695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men.
    Nijland EA; Strasburger CJ; Popp-Snijders C; van der Wal PS; van der Veen EA
    Eur J Endocrinol; 1998 Oct; 139(4):395-401. PubMed ID: 9820615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute administration of hexarelin stimulates GH secretion during day and night in normal men.
    Loche S; Colao A; Cappa M; Ferone D; Merola B; Faedda A; Imbimbo BP; Deghenghi R; Lombardi G
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):275-9. PubMed ID: 9156035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study.
    Massoud AF; Hindmarsh PC; Brook CG
    J Clin Endocrinol Metab; 1996 Dec; 81(12):4338-41. PubMed ID: 8954038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of body composition on hexarelin-induced growth hormone release in normal elderly subjects.
    Rahim A; O'Neill P; Shalet SM
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):659-64. PubMed ID: 10197083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats.
    Conley LK; Gaillard RC; Giustina A; Brogan RS; Wehrenberg WB
    J Endocrinol; 1998 Sep; 158(3):367-75. PubMed ID: 9846166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity.
    Grottoli S; Maccario M; Procopio M; Oleandri SE; Arvat E; Gianotti L; Deghenghi R; Camanni F; Ghigo E
    Eur J Endocrinol; 1996 Dec; 135(6):678-82. PubMed ID: 9025712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hexarelin as a test of pituitary reserve in patients with pituitary disease.
    Korbonits M; Kaltsas G; Perry LA; Grossman AB; Monson JP; Besser GM; Trainer PJ
    Clin Endocrinol (Oxf); 1999 Sep; 51(3):369-75. PubMed ID: 10469018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.